Biosciences Accelerator

Overview

The Accelerator for Translational Biosciences at The Hamner Institutes for Health Sciences provides emerging companies with access to a research facility with state-of-the-art equipment, as well as world-class scientific and business development support. The Accelerator is a unique resource for small companies that provides substantial infrastructure to assist their commercialization efforts.  Furthermore, the Accelerator fosters opportunities to develop collaborative research and educational programs among The Hamner, academia, industry, and government.  Partnerships build shared resources and increase funding opportunities, which add value for each of the participants.  This allows The Hamner, in collaboration with its institutional partners, to accelerate the commercialization of new technologies aimed at improving human health.

Current Hamner Accelerator Companies

Biomedomics, Inc.  (http://www.biomedomics.com/)

BioMedomics is developing advanced highly sensitive and quantitative rapid point-of-care (POC) diagnostic platforms and novel disease specific diagnostic tests for the $16 billion POC diagnostic market. The company’s goal is to make POC testing widely accessible with the same level of sensitivity and quantitation as complex and expensive central lab tests.

Chaperone Therapeutics, Inc.  (http://www.chaperonetherapeutics.com/)

Chaperone Therapeutics, Inc. (“Chaperone”) is an early-phase pharmaceutical company that is developing drugs to treat diseases associated with abnormal protein folding and aggregation. Many neurodegenerative diseases, such as Alzheimer’s disease, Parkinson’s disease, prion diseases, ALS (Lou Gehrig’s Disease) and Huntington’s disease are characterized by the abnormal aggregation of proteins in individuals with environmental exposure to proteotoxic stress or genetic vulnerability to the disease. Proteins that guide correct protein folding, chaperones, function as the cellular quality control mechanism to correct protein misfolding and to protect neurons from cell death. Chaperone is uniquely poised to develop novel drugs to ameliorate neurodegenerative disease based on the pharmacological enhancement of the body’s natural protein folding machinery.

Triangle Research Labs, LLC  (http://www.triangleresearchlabs.com/)

Triangle Research Labs (TRL) produces high quality hepatocytes for use in pre-clinical ADMETox applications. Their mission is to assist in the discovery and development of meaningful therapeutic agents that benefit the human condition. TRL provides both human and animal, fresh and cryopreserved hepatocytes, and their relevant media. A rapidly growing company, TRL has decades of experience in the hepatic sciences and is a leader in quality and service in the business.

Couragen Biopharmeceutics  (xxiao@email.unc.edu)

Couragen Biopharmaceutics, LLC is a North Carolina startup biotechnology company whose mission is to develop gene therapy and protein therapy products for pre-clinical and clinical use. Couragen uses a technology platform based on adeno-associate virus (AAV) vectors, a safe and powerful vehicle, to deliver therapeutic genes to a variety of cells, tissues and even the whole body for genetic and chronic diseases treatment. In addition, the company also provides custom-designed AAV vectors, which are in high demand as a tool for laboratory research such as molecular biology, genetics and mechanisms of pathogenesis and even engineering of animal models.

BindusChem  (info@binduschem.com)

BindusChem, LLC is a chemistry-based contract research service organization with a core business of custom synthesis. The company offers a variety of synthetic
chemistry services (from mg to kg quantities) to customers in a cost-effective and timely manner, specializing in small molecules, porphyrins, nucleosides and nucleotides, and heterocycles. BindusChem binds to customer focus, reliability and confidentiality.

MedBlue Incubator  (919-226-3082)

MedBlue Incubator, Inc. (MBI) is a for profit C corporation founded by the departments of Surgery, Pathology and Anesthesiology at the Duke University Medical Center.
The mission of MBI will be to help identify promising IP in the aforementioned Duke departments and to work seamlessly within those departments and with the Duke Office of Licensing & Ventures to advance the development of the IP to a liquidity event.

Contact

For more information on the Hamner Biosciences Accelerator, please submit the form on the Contact Us page, with “Biosciences Accelerator” selected from the drop-down menu under “Interest.”